AMI Cardiogenic Shock
Early Stabilization Can Improve Outcomes in Cardiogenic Shock
Impella® heart pumps have the ability to stabilize patient hemodynamics, unload the left ventricle, perfuse end organs, and allow for recovery of the native heart in patients with ongoing cardiogenic shock. Identifying patients early, treating them with a proven protocol, and following them with hemodynamic monitoring and aggressive down titration of inotropes and vasopressors can reverse the downward spiral of cardiogenic shock and help patients achieve myocardial recovery.
Explore the Education Library
Final Results from the NCSI Study Demonstrate the Benefit of Early Cardiac Unloading with Impella
The NCSI Study demonstrates a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization.
Achieving >70% AMI Cardiogenic Shock Survival: Insight from National Cardiogenic Shock Initiative (NCSI) Study
William O'Neill, MD, explains how cardiac power output (CPO) and pulmonary artery pulsatility index (PAPI) are used to drive care for patients after angioplasty.
Cardiogenic Shock Patients Can Achieve Heart Recovery
Dr. Shelley Hall, chief of transplant cardiology and mechanical support/heart failure at Baylor University Medical Center, discusses the challenges of creating trials to advance the science of cardiogenic shock.
Resources for Health Care Professionals
Learn more about how identifying patients early and adhering to a best practice protocol can help patients achieve myocardial recovery.
Explore clinical data that validates best practices in AMI cardiogenic shock management.
Review best practices for improving patient outcomes following cardiogenic shock.